Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

S&P Biotech SPDR (NY: XBI )

99.88 -0.12 (-0.12%)
Streaming Delayed Price Updated: 12:41 PM EST, Nov 29, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about S&P Biotech SPDR

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Fear & Greed In The Biotech Sector
With rates rising, widespread tax-loss selling, and fund manager’s either closing the books for 2021 or just closing down altogether, the market has entered a major risk off phase and biotech stocks... 
Via Talk Markets
Healthcare Stocks Are Winners And Provide Diversification To Your Portfolio
As we have written their year many times speculative small cap biotechs have not done well in 2021 since they peaked in February. 
Via Talk Markets
Top 10 Investment Themes For 2022
What are the investment trends going to look like for 2022? 
Via Talk Markets
ETF Battles: Which Biotech Stock ETF Is The Better Choice? - It's IBB Vs. XBI
A biotech clash between the iShares Biotechnology ETF and the SPDR S&P Biotech ETF. 
Via Talk Markets
The Bear Market Is Already Here – But Not For Dividend Investors
While the broad stock market indices remain at near-record levels, there are sectors of the market that have dropped into correction or even bear market territory over recent months. 
Via Talk Markets
Analyzing SPDR Series Trust SPDR S&P Biotech ETF's Unusual Options Activity
SPDR Series Trust SPDR S&P Biotech ETF (NYSE:XBI) shares... 
Via Benzinga
Topics Stocks
Exposures US Equities
Analyzing SPDR Series Trust SPDR S&P Biotech ETF's Unusual Options Activity
SPDR Series Trust SPDR S&P Biotech ETF (NYSE:XBI) shares... 
Via Benzinga
Topics Stocks
Exposures US Equities
Biotech Playbook 2021 Part 2: Rotation Rally Brings Relief after FED Pivot
The new aggressive Fed taper combined with a rise in interest rates for 2022 adds a new element of risk to portfolio management. Monetary policy is a headwind for 2022. 
Via Talk Markets
10 Bargain Stocks to Buy After Falling 30% in 2021
If you’re looking for bargain stocks to buy that are down 30% or more in 2021, that’s not an easy task. Here are 10 that fit the bill. 
Via InvestorPlace
Biotech Playbook 2021: No Help From Small Caps In Q4
Mid-cap stock picks have done better today but are way off their 2021 highs. Cryoport and Veracyte are still up and look better technically. Quidel was up 5.48% today on Omicron concerns globally but... 
Via Talk Markets
8 Monster Stock Market Predictions – The Week Of December 13, 2021 Edition
Via Talk Markets
5 Top-Ranked ETFs to Buy At Bargain Prices
The beaten-down prices have charged up investors to snap up ETFs on the cheap. Investors could definitely look to these products for outsized gains over the longer term. 
Via Talk Markets
How Did Healthcare Stocks Perform Over This Volatile Month?
It’s been a rough month for small-cap biotech stocks amidst a general correction in the market which brought general indices down about 10%. 
Via Talk Markets
Tuesday Talk: O(micron) - Pow(ell)!
As Wall St. investors await the market open Tuesday, futures dive on Omicron concerns as well as anticipation surrounding Yellen and Powell's Senate testimony this morning. 
Via Talk Markets
Stocks Rise On November 29 On Predictable Volatility Crush
Stocks jumped on November 29 as volatility came down sharply. 
Via Talk Markets
COVID Is Back Disrupting Markets And Causing More Sector Uncertainty
Just when you were having an enjoyable four day weekend cruising along the interminable bull market COVID is back disrupting trends. Healthcare stocks held up reasonably well .Will there be new respect... 
Via Talk Markets
Biotech Stocks are Due for a Rally
There are many rebalancing trades left in your stock portfolio but biotech is in the doldrums. 
Via Talk Markets
Looking for Growth in Small and Mid Cap Life Science Stocks
2021 is an unusual year for biotech with a “blow-off” February high in speculative small caps. 
Via Talk Markets
How Are Biotech ETFs Reacting To These Q3 Earnings Releases?
There's no denying that the pandemic has opened up investment opportunities in the biotech sector by triggering a race to introduce vaccines. Let’s take a look at big biotech earnings releases to see... 
Via Talk Markets
Wednesdays With Wedbush On PreMarket Prep Plus
On the PreMarket Prep Plus "Wednesday’s With Wedbush" segment, Sahak Manuelian, managing director and head of equi... 
Via Benzinga
15 Charts All Traders Should Look At Every Morning
One of the hardest things to do as a day trader is gathering all the necessary information to execute profitable trades. Below are the to... 
Via Benzinga
Look For The Q4 Biotech Bounce In Mid-Small Caps
Large-cap biopharma stocks are off their highs because of prospects that drug prices may be directly negotiated through Medicare but several Democrats are not in agreement as to how this could be best... 
Via Talk Markets
Small Cap Biotechs Sagging But More Deals Are Likely to Perk Up the Market
Despite record highs in the Nasdaq recently at the 15,000 level the biotech market seems sluggish. Speculation has ebbed. As if we need a green screen every day. 
Via Talk Markets
Healthcare Stocks Hit New Highs but Small Caps Lag
Many smaller cap biotech stocks trade on news and milestones and have no earnings so require more expertise in the field. 
Via Talk Markets
ETF Reflections: US Stocks
I'm a bear. So the longer they prop this dreck up, the greater the fall. Suits me! 
Via Talk Markets
Biotech ETFs To Benefit From Latest Booster Update
Vaccine makers like Moderna and Pfizer have reasons to cheer the update with regard to the application of boosters. The U.S. government announced plans to make COVID-19 vaccine boosters available from... 
Via Talk Markets
Exposures COVID-19
Analyzing SPDR Series Trust SPDR S&P Biotech ETF's Unusual Options Activity
On Monday, shares of SPDR Series Trust SPDR S&P Biotech ETF (NYSE:XBI) saw unusual options activity. After the option alert, the stock price moved down to $122.44. Sentiment... 
Via Benzinga
Topics Stocks
Exposures US Equities
Large Cap Biopharma Stocks provide Growth and Value
The S&P 500 Healthcare Index was up 0.53% and biotech still lags in healthcare yet Large Cap Biopharma is doing well YTD. 
Via Talk Markets
Topics Stocks
Exposures US Equities
ETF Investing Areas to Consider for August
There is no doubt that the second-quarter 2021 earnings season is going strong. 
Via Talk Markets
Carter Worth And Mike Khouw's XBI Trade
On CNBC's "Options Action," Carter Worth of Cornerstone Macro said SPDR S&P Biotech ETF (NYSE: XBI) has a bounce potential, having sold off to support. XBI is an... 
Via Benzinga
Topics Stocks
Exposures US Equities
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.